These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 28916537)

  • 1. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.
    Plavina T; Muralidharan KK; Kuesters G; Mikol D; Evans K; Subramanyam M; Nestorov I; Chen Y; Dong Q; Ho PR; Amarante D; Adams A; De Sèze J; Fox R; Gold R; Jeffery D; Kappos L; Montalban X; Weinstock-Guttman B; Hartung HP; Cree BAC
    Neurology; 2017 Oct; 89(15):1584-1593. PubMed ID: 28916537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble serum VCAM-1, whole blood mRNA expression and treatment response in natalizumab-treated multiple sclerosis.
    Petersen ER; Søndergaard HB; Oturai AB; Jensen P; Sorensen PS; Sellebjerg F; Börnsen L
    Mult Scler Relat Disord; 2016 Nov; 10():66-72. PubMed ID: 27919501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab.
    Koudriavtseva T; Sbardella E; Trento E; Bordignon V; D'Agosto G; Cordiali-Fei P
    Clin Exp Immunol; 2014 Jun; 176(3):320-6. PubMed ID: 24387139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS.
    Ghezzi A; Comi G; Grimaldi LM; Moiola L; Pozzilli C; Fantaccini S; Gallo P
    Neurol Neuroimmunol Neuroinflamm; 2019 Sep; 6(5):e591. PubMed ID: 31355324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing.
    Foley JF; Goelz S; Hoyt T; Christensen A; Metzger RR
    Mult Scler Relat Disord; 2019 Jun; 31():65-71. PubMed ID: 30939392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies.
    Sehr T; Proschmann U; Thomas K; Marggraf M; Straube E; Reichmann H; Chan A; Ziemssen T
    J Neuroinflammation; 2016 Jun; 13(1):164. PubMed ID: 27349895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial.
    Wessels H; von Richter O; Velinova M; Höfler J; Chamberlain P; Kromminga A; Lehnick D; Roth K
    Expert Opin Biol Ther; 2023; 23(12):1287-1297. PubMed ID: 38044885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.
    Fox RJ; Cree BA; De Sèze J; Gold R; Hartung HP; Jeffery D; Kappos L; Kaufman M; Montalbán X; Weinstock-Guttman B; Anderson B; Natarajan A; Ticho B; Duda P;
    Neurology; 2014 Apr; 82(17):1491-8. PubMed ID: 24682966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The frequency of occurrence of atypical lymphocytes in peripheral blood smears of natalizumab-treated patients with multiple sclerosis.
    Robier C; Amouzadeh-Ghadikolai O; Bregant C; Diez J; Melinz K; Quehenberger F; Quasthoff S
    Int J Lab Hematol; 2017 Oct; 39(5):469-474. PubMed ID: 28481019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble VCAM-1 impairs human brain endothelial barrier integrity via integrin α-4-transduced outside-in signalling.
    Haarmann A; Nowak E; Deiß A; van der Pol S; Monoranu CM; Kooij G; Müller N; van der Valk P; Stoll G; de Vries HE; Berberich-Siebelt F; Buttmann M
    Acta Neuropathol; 2015 May; 129(5):639-52. PubMed ID: 25814153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study.
    Saida T; Kira JI; Kishida S; Yamamura T; Sudo Y; Ogiwara K; Tibung JT; Lucas N; Subramanyam M;
    Mult Scler Relat Disord; 2017 Jan; 11():25-31. PubMed ID: 28104251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
    Wipfler P; Oppermann K; Pilz G; Afazel S; Haschke-Becher E; Harrer A; Huemer M; Kunz A; Golaszewski S; Staffen W; Ladurner G; Kraus J
    Mult Scler; 2011 Jan; 17(1):16-23. PubMed ID: 20937631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis.
    Foley JF; Defer G; Ryerson LZ; Cohen JA; Arnold DL; Butzkueven H; Cutter GR; Giovannoni G; Killestein J; Wiendl H; Li K; Dsilva L; Toukam M; Ferber K; Sohn J; Engelman H; Lasky T
    Neurol Neuroimmunol Neuroinflamm; 2024 Dec; 11(6):e200321. PubMed ID: 39393045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1) and Natalizumab Serum Concentration as Potential Biomarkers for Pharmacodynamics and Treatment Response of Patients with Multiple Sclerosis Receiving Natalizumab.
    Auer M; Bauer A; Oftring A; Rudzki D; Hegen H; Bsteh G; Di Pauli F; Berek K; Zinganell A; Berger T; Reindl M; Deisenhammer F
    CNS Drugs; 2022 Oct; 36(10):1121-1131. PubMed ID: 36173556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study.
    O'Connor P; Goodman A; Kappos L; Lublin F; Polman C; Rudick RA; Hauswirth K; Cristiano LM; Forrestal F; Duda P
    Neurology; 2014 Jul; 83(1):78-86. PubMed ID: 24898925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of integrin expression on monocytes in multiple sclerosis patients treated with natalizumab.
    Dallari S; Franciotta D; Carluccio S; Signorini L; Gastaldi M; Colombo E; Bergamaschi R; Elia F; Villani S; Ferrante P; Delbue S
    J Neuroimmunol; 2015 Oct; 287():76-9. PubMed ID: 26439965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis.
    Harrer A; Pilz G; Einhaeupl M; Oppermann K; Hitzl W; Wipfler P; Sellner J; Golaszewski S; Afazel S; Haschke-Becher E; Trinka E; Kraus J
    PLoS One; 2012; 7(2):e31784. PubMed ID: 22363732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natalizumab therapy for highly active pediatric multiple sclerosis.
    Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
    JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?
    Aguirre C; Meca-Lallana V; Barrios-Blandino A; Del Río B; Vivancos J
    Mult Scler Relat Disord; 2020 Sep; 44():102250. PubMed ID: 32531754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
    Rudick RA; Sandrock A
    Expert Rev Neurother; 2004 Jul; 4(4):571-80. PubMed ID: 15853576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.